Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
FDA Win Boosts Struggling Pharmaceutical Stock
09:52am, Monday, 18'th Aug 2025
Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug Wegovy landed Food and Drug Administration (FDA) approval to be used in the tre
Novo Nordisk stock soar 5% today: here's why analysts are bullish
09:42am, Monday, 18'th Aug 2025
Novo Nordisk stock jumped about 5% in pre-market trading, boosted by good news around its obesity drug Wegovy. The FDA has just cleared the drug for use in treating alcoholic steatohepatitis (ASH), a
Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease
09:40am, Monday, 18'th Aug 2025
U.S.-listed shares of Novo Nordisk (NVO) gained 4% in premarket trading after the Food and Drug Administration (FDA) approved the pharmaceutical firm's popular weight-loss drug, Wegovy, to treat a ser
Novo Nordisk to offer Ozempic for $499 per month
09:07am, Monday, 18'th Aug 2025
Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients to access authentic Ozempic for $499 per month.
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
09:00am, Monday, 18'th Aug 2025
Novo Nordisk said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price through multiple platforms. Patients can pay $499 in cash
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact The Gross Law Firm
08:45am, Monday, 18'th Aug 2025
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class peri
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.
06:43am, Monday, 18'th Aug 2025
Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and Ozempic for diabetes.
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
05:00am, Monday, 18'th Aug 2025
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
04:56am, Monday, 18'th Aug 2025
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk"
Novo Nordisk shares are rising. The FDA approves another use for Wegovy.
04:21am, Monday, 18'th Aug 2025
Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy to treat a form of liver disease.
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
04:08am, Monday, 18'th Aug 2025
Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of i
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such in
1 Stock Down 40% This Year to Buy and Hold
10:00am, Sunday, 17'th Aug 2025
Novo Nordisk (NVO 2.87%) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market.
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
07:15am, Sunday, 17'th Aug 2025
After crushing the market over the past few years, Eli Lilly (LLY 2.73%) is finally feeling the effects of gravity. The company has faced a pair of setbacks this year.
